Flagship explainer
What drives Spero Therapeutics, Inc.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| $8.6M | FY2025 |
| |
| Income before tax | $8.8M | FY2025 |
|
| Operating income | $6.3M | FY2025 |
|
| $12.6M | FY2025 |
| |
| Ending assets | $68.9M | FY2025 |
|
| Beginning assets | $111M | FY2024 |
|
| $59M | FY2025 |
| |
| $46.1M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001193125-26-126192